Brief: Neurosense CEO Provides Q1 2023 Update Phase 2B Als Trial Achieves 80% Enrollment

Neurosense Therapeutics

17/04/2023 14:09

April 17 (Reuters) - Neurosense Therapeutics Ltd
 NRSN.O :
    * NEUROSENSE CEO PROVIDES Q1 2023 UPDATE: PHASE 2B ALS TRIAL
ACHIEVES 80% ENROLLMENT
    * NEUROSENSE THERAPEUTICS LTD - PHASE 2B AMYOTROPHIC LATERAL
SCLEROSIS (ALS) PARADIGM TRIAL ACHIEVES 80% PATIENT ENROLLMENT
    * NEUROSENSE THERAPEUTICS LTD -  PHASE 2B AMYOTROPHIC
LATERAL
SCLEROSIS ENROLLMENT ON TRACK TO BE COMPLETED H1 2023
    * NEUROSENSE THERAPEUTICS LTD -  PHASE 2B AMYOTROPHIC
LATERAL
SCLEROSIS TOPLINE RESULTS EXPECTED H2 2023

Source text for Eikon:  ID:nPn6wr9wa 
Further company coverage:  NRSN.O